Cristália Readies Phase 1 Trial of Polilaminina for Spinal Injury

Cristália’s Phase 1 safety trial of polilaminina for acute spinal cord trauma was scheduled to begin 24 September 2026 after authorisation from Brazil’s health regulator, Anvisa, in January — with a peer-reviewed pilot now published but efficacy still unproven.

A flat editorial illustration depicting the structured pathway of a clinical trial, with abstract geometric forms representing regulatory gates, patient enrolment, and institutional progress across a warm cream background in deep teal, coral, and amber.

CLINICAL CATALYST · SPINAL CORD THERAPY · SEPTEMBER 26, 2026 · BRAZIL

Before a single efficacy result has been confirmed in a controlled trial, polilaminina — a therapy based on laminin, a protein isolated from placentas, developed at the Universidade Federal do Rio de Janeiro (UFRJ) — has already generated R$150 million in private investment and 33 compassionate-use authorisations. The start of a formal Phase 1 clinical trial, scheduled for 24 September 2026, marks the point at which the programme moves from pre-clinical promise and judicial access into the structured evidentiary process that the Agência Nacional de Vigilância Sanitária (Anvisa), Brazil’s national health regulator, requires before any commercial registration can be considered.

Laboratório Cristália, a Brazilian pharmaceutical company, is the trial sponsor. Anvisa authorised the Phase 1 study in January 2026. The study will enrol five patients aged 18 to 72 with complete, acute thoracic spinal cord injuries between vertebrae T2 and T10, sustained within 72 hours of enrolment — a narrow eligibility window that reflects both the biological rationale for early intervention and the practical difficulty of recruiting within that timeframe. The trial sites are Hospital das Clínicas de São Paulo and Santa Casa de Misericórdia de São Paulo, according to Agência Brasil, and neurosurgeons were scheduled to be trained in the procedure before enrolment, according to Folha Vitória. The primary endpoint is safety, not efficacy; the study is explicitly designed to characterise the adverse-event profile of a single intramedullary application of a 100-microgram-per-millilitre polilaminina formulation, not to demonstrate that the treatment works.

What the pilot study confirms — and does not

The evidentiary foundation for the Phase 1 trial is a pilot study published on 4 August 2026 in Spinal Cord, a Nature-portfolio journal specialising in spinal cord medicine. The study, led by biologist Tatiana Coelho de Sampaio of UFRJ, enrolled eight patients between December 2016 and January 2021. All presented with severe spinal cord injury classified as grade A — the most complete form of motor and sensory loss — on the American Spinal Injury Association (ASIA) Impairment Scale (AIS). Six of the eight showed an improvement of at least two AIS grades — five to AIS C and one to AIS D, less severe classifications associated with partial motor recovery — according to the published article as reported by Folha de Pernambuco and Só Notícia Boa. Three of the eight patients died during the follow-up period; the cases were reviewed by the Comissão Nacional de Ética em Pesquisa (CONEP), Brazil’s national research ethics commission, and by an external physician, and the authors concluded that the deaths were not related to polilaminina, per Só Notícia Boa.

The article’s own conclusion is unambiguous on one point: the pilot provides a proof of concept and a safety signal in a small group, but does not permit conclusions about efficacy. As the authors note, the absence of a control group prevents any causal inference: spontaneous partial recovery after acute spinal cord trauma is documented in the medical literature, meaning that improvement observed in uncontrolled cases cannot be attributed to the drug without a controlled comparator arm.

Ogari Pacheco, founder and president of Cristália’s board, said in April 2026 that the company would invest ‘whatever is necessary for the success of the innovation,’ without specifying a forward budget. The R$150 million figure covers Cristália’s development spending since it joined the programme in 2018, per Panorama Farmacêutico.

Patent position and the regulatory path

The intellectual-property situation is layered. UFRJ filed a patent in 2007 protecting the polilaminina molecule itself, but lost international exclusivity around 2017 after failing to pay maintenance fees. The Brazilian national patent remains in force but expires in 2027. Cristália filed a separate patent application for the manufacturing process in Brazil in 2022 and, in 2023, abroad in markets including the United States, Europe, India, China, South Korea, and Latin America; these applications cover the manufacturing process, not the molecule. All remain under review, per Panorama Farmacêutico.

The regulatory path to commercialisation, if the Phase 1 trial proceeds without safety signals that halt it, runs from a five-patient safety study through Phase 2 dose-finding and Phase 3 efficacy trials with adequate statistical power and a controlled comparator. No competitor product or rival programme in spinal cord regeneration has been named in the available record as a direct comparator at the same regulatory stage in Brazil.

The judicial channel has already created a parallel access pathway that sits outside the trial. As of March 2026, Brazilian courts had issued 59 decisions on polilaminina access, and Anvisa had authorised 33 patients to use it outside clinical studies, according to Poder360. Cristália donates the doses for approved cases through Anvisa’s compassionate-use programme, per the same report. These compassionate-use cases sit outside the formal trial, so their outcomes — positive or negative — will not form part of the controlled evidentiary record that Anvisa will eventually evaluate.

The principal friction is not scientific but structural. A Phase 1 trial of five patients generates a safety dataset, not an approval dossier. The gap between the public narrative — which has already produced a national celebrity scientist in Sampaio and a wave of court petitions — and the evidentiary standard Anvisa must apply is the operative risk for the programme. If interim safety data from the Phase 1 study are communicated publicly before Phase 2 is designed, the pattern of judicial access applications is likely to intensify, further straining Cristália’s commitment to supply doses at no charge and potentially complicating patient recruitment for the controlled phases that would actually support registration. No analyst estimate of the addressable market or peak-sales projection for polilaminina has been published in the available record; no payer or public-procurement body has indicated a coverage or reimbursement position.

What to Watch

  1. Safety data from the five-patient Phase 1 cohort at Hospital das Clínicas and Santa Casa de Misericórdia de São Paulo, expected after the six-month follow-up period concludes
  2. The status of Cristália’s patent applications in Brazil and the several international markets where filings are pending — a granted process patent would materially alter the competitive landscape for any future generic entrant
  3. Whether Anvisa issues any guidance on the judicial compassionate-use pipeline, given that those cases are not integrated into the formal trial record
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

The peer-reviewed publication in Spinal Cord is the programme’s most durable asset to date — not because it confirms efficacy, but because it converts a preprint and a press event into a citable, refereed safety signal. That distinction matters: it is the document Anvisa will use as the baseline when evaluating Phase 1 results, and it is the document that any future Phase 2 protocol will have to engage with directly.

Polilaminina Development Timeline

2016–2021
Pilot study: 8 patients enrolled. 6 of 8 improved by at least two AIS grades from AIS A. 3 deaths, reviewed by CONEP and an external physician; the authors concluded they were unrelated to polilaminina.
c. 2017
UFRJ international patent exclusivity lapsed.
2022
Cristália filed manufacturing-process patent in Brazil.
2023
Cristália filed international patents (US, Europe, India, China, South Korea, Latin America).
January 2026
Anvisa authorised Phase 1 trial. Formulation: 100 micrograms per millilitre. Planned enrolment: 5 patients.
March 2026
59 court decisions on compassionate access. 33 patients authorised by Anvisa for compassionate use.
24 September 2026
Phase 1 trial scheduled to begin at Hospital das Clínicas and Santa Casa de Misericórdia de São Paulo.
Investment to date: R$150 million. Sources: Agência Brasil, Folha Vitória, Folha de Pernambuco, Só Notícia Boa, Poder360, Panorama Farmacêutico.

Why this is relevant

Patients

Polilaminina is entering formal Phase 1 testing in five patients with acute thoracic spinal cord injury; access outside the trial remains limited to compassionate-use authorisations. The pilot study reports a safety signal in eight cases but explicitly draws no efficacy conclusions.

Industry

Cristália has committed R$150 million to date and holds pending patent applications covering the manufacturing process across Brazil and several international markets, all still under review. The company is donating compassionate-use doses, creating an open-ended cost obligation that runs parallel to the formal trial.

Payers

No public payer, national procurement body, or private insurer has indicated a coverage or reimbursement position for polilaminina. The available record does not include any health-technology assessment filing or pricing negotiation, suggesting that payer engagement is unlikely before Phase 2 data are available.

Litigation

Brazilian courts had issued 59 decisions on compassionate access by March 2026, and Anvisa had authorised 33 patients. Those cases are not integrated into the formal trial record, which may complicate both the evidentiary pathway and Cristália’s supply commitments if the volume of judicial applications continues to grow during Phase 1.

Sources: Folha Vitória · Folha de Pernambuco · Poder360 · Panorama Farmacêutico · Agência Brasil · Só Notícia Boa · Anvisa · Spinal Cord

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related